{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:54:43Z","timestamp":1781931283587,"version":"3.54.5"},"reference-count":13,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"DOI":"10.25259\/ijdvl_1306_20","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T05:43:24Z","timestamp":1629870204000},"page":"93-96","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunotherapy-intensified paraneoplastic dermatomyositis"],"prefix":"10.25259","volume":"88","author":[{"given":"A.","family":"Estenaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rodriguez-Garijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tom\u00e1s-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Anto\u00f1anzas-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Alvarez-Gigli","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garc\u00eda-Tobar","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Espaa-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Salido-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"10.25259\/IJDVL_1306_20\/ref-1","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.3892\/ol.2018.9409","article-title":"Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol Lett"},{"key":"10.25259\/IJDVL_1306_20\/ref-2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: A meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.25259\/IJDVL_1306_20\/ref-3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1306_20\/ref-4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1684\/ejd.2016.2770","article-title":"A case of drug-associated dermatomyositis following ipilimumab therapy","volume":"26","author":"Yamaguchi","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_1306_20\/ref-5","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced Lung adenocarcinoma with nivolumab-associated dermatomyositis","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"key":"10.25259\/IJDVL_1306_20\/ref-6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 Inhibitor-associated myopathies: Emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"10.25259\/IJDVL_1306_20\/ref-7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma","volume":"104","author":"Berger","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.25259\/IJDVL_1306_20\/ref-8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jdcr.2018.08.006","article-title":"Wong-type dermatomyositis during anti-PD-1 therapy","volume":"4","author":"Yu","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_1306_20\/ref-9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature","volume":"30","author":"Kosche","year":"2020","journal-title":"Melanoma Res"},{"key":"10.25259\/IJDVL_1306_20\/ref-10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13256-019-2105-9","article-title":"Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report","volume":"13","author":"Shibata","year":"2019","journal-title":"J Med Case Rep"},{"key":"10.25259\/IJDVL_1306_20\/ref-11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting antinuclear antibodies","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.25259\/IJDVL_1306_20\/ref-12","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1111\/1346-8138.14993","article-title":"Case of dermatomyositis during treatment with pembrolizumab for lung cancer","volume":"46","author":"Hinogami","year":"2019","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_1306_20\/ref-13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/immunotherapy-intensified-paraneoplastic-dermatomyositis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/immunotherapy-intensified-paraneoplastic-dermatomyositis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T11:57:37Z","timestamp":1679313457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/immunotherapy-intensified-paraneoplastic-dermatomyositis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":13,"alternative-id":["10.25259\/IJDVL_1306_20"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1306_20","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"article-number":"93"}}